Literature DB >> 16565965

Regional alterations in RGS4 protein in schizophrenia.

Holly A Erdely1, Carol A Tamminga, Rosalinda C Roberts, Michael W Vogel.   

Abstract

The regulator of G protein signaling (RGS) molecules are a class of proteins that modulate the signaling activity of G-protein coupled receptors. Regulator of G protein signaling 4 (RGS4) is of particular interest in schizophrenia since it is associated with the dopamine (DA) receptor, its expression is altered in affected CNS tissue, and polymorphisms in the RGS4 gene are being examined as risk factors for the disease (Morris et al.2004, Am J Med Genet B Neuropsychiatr Genet 125:50-53; Prasad et al.2005, Mol Psychiatry 10:213-219; Williams et al.2004, Biol Psychiatry 55:192-195). To further test for the involvement of RGS4 expression in schizophrenia, we examined a selection of different cortical and subcortical regions in human brain for alterations in RGS4 mRNA and protein expression. To evaluate the effect of antipsychotic medication on RGS4 expression levels, we compared a subset of treated and untreated cases that were off antipsychotic medication for at least 3 months prior to death. We report a significant decrease in RGS4 mRNA levels in the cingulate gyrus, superior frontal gyrus, and the insular cortex of all schizophrenia cases when compared with controls. A decrease in RGS4 mRNA was also observed in the caudate, but only in the medicated schizophrenia cases. Measurement of protein levels using Western blot demonstrated that RGS4 protein is decreased in the frontal cortex of schizophrenia cases. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565965     DOI: 10.1002/syn.20265

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  39 in total

Review 1.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 2.  Gene expression in the etiology of schizophrenia.

Authors:  Nicholas J Bray
Journal:  Schizophr Bull       Date:  2008-03-11       Impact factor: 9.306

3.  Microfabricated channel array electrophoresis for characterization and screening of enzymes using RGS-G protein interactions as a model system.

Authors:  Jian Pei; John F Dishinger; David L Roman; Chetwana Rungwanitcha; Richard R Neubig; Robert T Kennedy
Journal:  Anal Chem       Date:  2008-05-09       Impact factor: 6.986

Review 4.  Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Int J Dev Neurosci       Date:  2011-02-21       Impact factor: 2.457

5.  Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.

Authors:  David L Roman; John R Traynor
Journal:  J Med Chem       Date:  2011-09-29       Impact factor: 7.446

Review 6.  Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.

Authors:  Nao J Gamo; Amy F T Arnsten
Journal:  Behav Neurosci       Date:  2011-06       Impact factor: 1.912

7.  Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Authors:  G Rivero; A M Gabilondo; J A García-Sevilla; L F Callado; R La Harpe; B Morentin; J J Meana
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

8.  Cloning and characterization of rabbit Rgs4 promoter in gut smooth muscle.

Authors:  Fang Li; Karnam S Murthy; Kamel Khalili; Wenhui Hu
Journal:  Gene       Date:  2009-11-26       Impact factor: 3.688

Review 9.  Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses.

Authors:  Amy F T Arnsten; Min J Wang; Constantinos D Paspalas
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 10.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.